Combination treatment effectively intercepts advanced acute cardiac rejection.
Antoniou
E A
EA
Transplant Microsurgery Laboratory, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Xu
M
M
Howie
A
A
Chondros
K
K
McMaster
P
P
D'Silva
M
M
D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy* / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology* / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D011798:Quinaldines
D001713:Biphenyl Compounds; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D000077339:Leflunomide; D009173:Mycophenolic Acid; C046943:brequinar; D011798:Quinaldines